Latest news

Filter News Articles



Vumerity medication for relapsing-remitting MS, now approved under PBS

Vumerity® (diroximel fumarate) will be listed under the Pharmaceutical Benefit Scheme (PBS).

A graphic with the words Medication update written on it.
We thank Ros Harman

Ros Harman has announced her resignation from the MSWA Board after 18 years of service and valued contribution.

Professional photograph of Ros Harman.
Researcher in Focus: Professor Bruno Meloni

MSWA is proud to be funding this important West Australian research, led by Professor Bruni Meloni, that will potentially provide the first effective treatment to minimise the damage that occurs in the early phases of stroke.

Professor Bruno Meloni at the Perron Institute's labs.
Employment & Workplace Survey Results Released for World MS Day

The survey, where 1,748 Australians (of which 525 are living with MS) participated, revealed there is a disconnect between expectations and workplace realities for those with a health condition.

Briefcase icon on orange background.
Staying connected this World MS Day

Margaret Cable, from Toodyay, was diagnosed with MS in the early days of COVID-19. Her story is a heartening example of “I connect, we connect” – the official tagline of World MS Day 2022.

World MS Day graphic - I connect, we connect.
International Nurses Day

International Nurses Day is our chance to say thank you and show our appreciation to those who go above and beyond each and every day, our nurses.

Icon displaying two cupped hands holding a heart with a cross inside it.
Research in Focus: SPIN

Professor Moira Sim from Edith Cowan University talks about the Systematic Profiling in Neurological Conditions (SPIN) research project.

Portrait style photo of Professor Moira Sim smiling for the camera.
An update about COVID-19

MSWA remains alert as we monitor the COVID-19 situation. This article provides a current updates and useful links for further information.

Research in Focus: TONiC

TONiC aims to identify the factors most affecting quality of life for people with motor neurone disease and Parkinson’s, and how outcomes and services could be improved. The research also explores the role of genetic and environmental factors associated with neurological diseases.

Professor Sulev Kõks smiling for the camera while standing in front of a Perron Institute banner.
Newly developed therapy could provide a bright light for Western Australians suffering with poor sleep and fatigue

An MSWA funded research project will trial specially made glasses to see the effects of light therapy on fatigue and excessive daytime sleepiness.

Newly developed therapy for people experiencing poor sleep and fatigue.